Search Tufts Medicine

Displaying 81 - 100 of 147
page
...
Real innovation starts with real people. Our doctors and researchers never stop working to advance medicine that improves healthcare for all. One way we do so is through clinical studies that explore new drugs, therapies, medical devices and clinical and surgical methods. Be part of medicine's evolution by participating in a clinical trial at Tufts Medicine.
Clinical Trials
page
...
The Neuro-Critical Care Fellowship at Tufts Medical Center in Boston is a two year, UCNS-accredited fellowship in preparation for sub-specialization in the care and management of patients in neurointensive care as well as clinical research, education and quality improvement practices.
page
...
With the explosion in novel cancer therapies, cancer outcomes have improved dramatically resulting in a growing population of cancer survivors. Simultaneously, there has been a rise in cardiovascular side effects of these cancer therapies that is limiting quality of life and life expectancy of cancer survivors.
clinical trial
...

The purpose of this research study is to explore the challenges of recognizing stroke in young adults, the process of making treatment decisions, and the patient’s understanding of the risk of recurrence and long term consequences of stroke. This study consists of a 30 to 60 minute interview of patients with prior stroke (ischemic stroke, transient ischemic attack, or intracerebral hemorrhage) who were 18-50 years of age at the time of stroke onset.
Patient Stories
August 10, 2020
Patient recognized the signs of stroke and got help immediately.
page
...
The Interventional Cardiology Fellowship Program at Tufts Medical Center in Boston is a 1-year advanced fellowship for cardiovascular specialists seeking interventional expertise.
clinical trial
...

The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
page
...
The faculty and team of the Institute for Clinical Research and Health Policy Studies (ICRHPS) at Tufts Medical Center regularly present their research in articles published in the world’s most prestigious, peer-reviewed journals and by the Agency for Healthcare Research and Quality.
Articles
May 14, 2021
May is American Stroke Month. Do you know there are things you can do with your diet to reduce your risk of having a stroke?
page
...
The MCRI sponsors Multidisciplinary Research Groups that foster collaboration among clinical, translational and basic scientists including MCRI faculty and investigators across Tufts Medicine and Tufts University. These groups include the Cardio-Oncology Research Group, the Cardio-Renal Research Group, the Vasculo-Neuro Research Group, the Women’s Cardiovascular Health Research Group, and the Wound Healing Research Group.
clinical trial
...

The purpose of this study is to learn if asundexian is safe for the participants, how it affects the body, and to look at how well it works to prevent future ischemic strokes in participants who already had had an acute non-cardioembolic ischemic stroke or high-risk TIA.
page
...
Apply for the neurology residency program at Tufts Medicine Tufts Medical Center in Boston and advance your career in neurology by learning from top doctors and surgeons.
clinical trial
...

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NIH StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.
clinical trial
...

Abbott developed the AMPLATZER™  PFO Occluder as a minimally invasive, transcatheter PFO closure treatment to further reduce the risk of recurrent stroke among patients with PFO and cryptogenic stroke beyond that achieved with medical management. This additional risk reduction is achieved by blocking the pathway for a venous embolism from reaching the body's arterial system and the brain.
clinical trial
...

The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE)
clinical trial
...

The purpose of this study is to see if the study drug, elezanumab, is safe and able to improve cognitive and/or motor functioning in an individual following the occurrence of acute ischemic stroke. This is a 52-week, Phase 2a, randomized, double-blind, parallel-group, placebo-controlled, multicenter proof-of concept study.
clinical trial
...

REACT-AF is a multicenter, prospective, randomized clinical trial comparing two treatment strategies for stroke prevention in patients with a history of paroxsymal or persistent atrial fibrillation and moderate stroke-risk.